Last updated on October 2018

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Brief description of study

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.

Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis.

CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Clinical Study Identifier: NCT02158858

Contact Investigators or Research Sites near you

Start Over

Debbie Johnson

Massachusetts General Hospital
Boston, MA United States
  Connect »

Debbie Johnson

Memorial Sloan-Kettering Cancer Center
New York, NY United States
  Connect »

Debbie Johnson

University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, PA United States
  Connect »

Wael Harb, MD

Horizon Oncology Center
Lafayette, IN United States
  Connect »

Marina Kremyanskya, MD PhD

Icahn School of Medicine at Mount Sinai
New York, NY United States
  Connect »

Nashat Gabrail, MD

Gabrail Cancer Center
Canton, OH United States
  Connect »

Gary Schiller, MD

UCLA Medical Center
Los Angeles, CA United States
  Connect »

Prithviraj Bose, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Lynda Foltz, MD

St. Paul's Hospital
Vancouver, BC Canada
  Connect »

Mark Heaney

Columbia University Medical Centre
New York, NY United States
  Connect »

Elena Liew, MD

University of Alberta Hospital
Edmonton, AB Canada
  Connect »

Brian Leber

Juravinski Cancer Centre
Hamilton, ON Canada
  Connect »

Vikas Gupta, MD

Princess Margaret Cancer Centre
Toronto, ON Canada
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.